ReviewLeukemia & lymphoma2016

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.

Claire N Harrison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.